Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | TOP1 | P11387 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.34 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | CCR8 | P51685 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2810868 | 1.00 | MAPT (0.35) | MAPTPOLBHTTSMARCA2KMT2A | |
| SCHEMBL2804928 | 0.86 | ADRB2 (0.40) | MAPTHTR1DHTR1BKDM4ETOP1 | |
| SCHEMBL2808536 | 0.86 | MAPT (0.41) | MAPTPOLBHTTKMT2ASMN1; SMN2 | |
| SCHEMBL2808539 | 0.86 | MAPT (0.41) | MAPTPOLBHTTKMT2ASMN1; SMN2 | |
| SCHEMBL2806930 | 0.85 | MEN1 (0.40) | MAPTPOLBHTTKMT2ASMN1; SMN2 | |
| SCHEMBL2806927 | 0.85 | MEN1 (0.40) | MAPTPOLBHTTKMT2ASMN1; SMN2 | |
| SCHEMBL2808446 | 0.84 | KDM4E (0.39) | MAPTPOLBHTTKMT2ASMN1; SMN2 | |
| SCHEMBL2808443 | 0.84 | KDM4E (0.39) | MAPTPOLBHTTKMT2ASMN1; SMN2 | |
| SCHEMBL2805554 | 0.82 | CCR1 (0.42) | MAPTPOLBHTTSMN1; SMN2NPSR1 | |
| SCHEMBL2808343 | 0.81 | HSP90AA1 (0.45) | MAPTPOLBHTTKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140011835-A1 | [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES | NOSCIRA, S.A. (ES) | 2014-01-09 | — | — | US | claimed |
| EP-2002863-A1 | [1,10]-phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases | NOSCIRA, S.A. (ES) | 2008-12-17 | — | — | EP | claimed |
| US-20140011835-A1 | [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES | NOSCIRA, S.A. (ES) | 2014-01-09 | — | — | US | disclosed |
| US-8592446-B2 | [1,10]-phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases | NOSCIRA, S.A. (ES) | 2013-11-26 | — | — | US | disclosed |
| US-20100240692-A1 | [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES | NOSCIRA, S.A. (ES) | 2010-09-23 | — | — | US | disclosed |
| EP-2170464-A2 | [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES | NOSCIRA, S.A. (ES) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008152068-A2 | [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES | NOSCIRA, S.A. (ES) | 2008-12-18 | — | — | WO | disclosed |
| EP-2002863-A1 | [1,10]-phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases | NOSCIRA, S.A. (ES) | 2008-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011835-A1 | [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES | HTT, PARK7, ATXN10 | MAPT 53/4885POLB 1719/4885HTT 1/4885 |
| US-20100240692-A1 | [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES | HTT, ATXN10, PSEN1 | MAPT 24/4885POLB 2095/4885HTT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.